Boston Scientific's Vanguard AAA Graft Effective For High-Risk Patients
This article was originally published in The Gray Sheet
Executive Summary
Preliminary data from a study of Boston Scientific's Vanguard aortic endograft for treatment of abdominal aortic aneurysms (AAA) show a 97.6% success rate in high-risk patients. The results reinforce a growing consensus among clinicians that the minimally invasive procedure is preferable to standard open surgery for this population.